gene

FTL

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about FTL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

118Connections

2Hypotheses

2Analyses

50Outgoing

47Incoming

0Experiments

2Debates

Summary

FTL encodes ferritin light chain, central to iron storage and antioxidant defense in the brain. Mutations cause neuroferritinopathy (NBIA), with relevance to Alzheimer's, Parkinson's, and other neurodegenerative diseases.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	FTL
Chromosome	19q13.33
Function	Fe²⁺ entry: Iron enters through 3-fold hydrophilic channels
Primary Expression	hippocampus, Hippocampus
Molecular Weight	20 kDa
Exons	4
Pathways	Lipid Metabolism, Mitophagy, Autophagy, Oxidative Stress, Ferroptosis
UniProt ID	[P02792](https://www.uniprot.org/uniprot/P02792)
GeneCards	FTL
Human Protein Atlas	FTL
Heteropolymer formation	12 FTL + 12 FTH1 subunits (optimal ratio)
Hollow shell	12-nm diameter cavity for iron storage
Ferroxidase center	Catalytic site for iron oxidation (primarily in heavy chain)
Iron nucleation sites	Light chain facilitates iron core formation
Shell stability	Provides structural integrity for the iron core
Associated Diseases	Als, Dystonia, Leukemia, Ms, Neurodegeneration
Interactions	ACSL4, ALZHEIMER, ALZHEIMER'S DISEASE, APP, APP/PS1, ATP13A2
SciDEX Hypotheses	Labile iron pool expansion amplifies genotype-spec
KG Connections	118 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

Wiki Pages (12)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    FTL["FTL"]
    FERRITINLIGHTPROTEIN["FERRITINLIGHTPROTEIN"]
    FTL -->|"component of"| FERRITINLIGHTPROTEIN
    Neurodegeneration{"Neurodegeneration"}
    FTL -->|"associated with"| Neurodegeneration
    Ms{"Ms"}
    FTL -->|"associated with"| Ms
    Parkinson{"Parkinson"}
    FTL -->|"associated with"| Parkinson
    Dystonia{"Dystonia"}
    FTL -->|"associated with"| Dystonia
    Depression{"Depression"}
    FTL -->|"inhibits"| Depression
    Alzheimer{"Alzheimer"}
    FTL -->|"inhibits"| Alzheimer
    FTL -->|"inhibits"| Ms
    Als{"Als"}
    FTL -->|"associated with"| Als
    Leukemia{"Leukemia"}
    FTL -->|"associated with"| Leukemia
    WDR45["WDR45"]
    FTL -->|"associated with"| WDR45
    COASY["COASY"]
    FTL -->|"associated with"| COASY
    ACSL4["ACSL4"]
    ACSL4 -->|"expressed in"| FTL
    TFR1["TFR1"]
    TFR1 -->|"expressed in"| FTL
    APP["APP"]
    APP -->|"inhibits"| FTL
    GPX4["GPX4"]
    GPX4 -->|"expressed in"| FTL
    SLC7A11["SLC7A11"]
    SLC7A11 -->|"expressed in"| FTL
    NRF2["NRF2"]
    NRF2 -->|"expressed in"| FTL
    FTH1["FTH1"]
    FTH1 -->|"expressed in"| FTL
    ERK["ERK"]
    ERK -->|"associated with"| FTL
    JAK["JAK"]
    JAK -->|"associated with"| FTL
    LGALS3["LGALS3"]
    LGALS3 -->|"associated with"| FTL
    PI3K["PI3K"]
    PI3K -->|"associated with"| FTL
    FGF19["FGF19"]
    FGF19 -->|"associated with"| FTL
    style FTL fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (71)

Target	Relation	Type	Str
FERRITINLIGHTPROTEIN	component_of	protein	0.90
Dystonia	associated_with	disease	0.65
Parkinson	associated_with	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Als	associated_with	disease	0.65
Leukemia	associated_with	disease	0.65
Als	inhibits	disease	0.65
Alzheimer	treats	disease	0.65
Depression	treats	disease	0.65
ALS	inhibits	disease	0.65
Ms	inhibits	disease	0.65
Alzheimer	inhibits	disease	0.65
Depression	inhibits	disease	0.65
GSH	inhibits	gene	0.60
Aβ	inhibits	protein	0.60
ALS	associated_with	disease	0.60
GSH	expressed_in	gene	0.60
GSH	activates	gene	0.60
TFR1	expressed_in	gene	0.60
FTH1	expressed_in	gene	0.60
APP	inhibits	gene	0.60
NRF2	expressed_in	gene	0.60
Rb	inhibits	protein	0.60
Ferroptosis	inhibits	pathway	0.60
APP/PS1	inhibits	gene	0.60
FERROPTOSIS	inhibits	gene	0.60
DEPRESSION	inhibits	gene	0.60
Oxidative Stress	inhibits	pathway	0.60
ALZHEIMER'S DISEASE	inhibits	gene	0.60
ROS	activates	gene	0.60
ACSL4	expressed_in	gene	0.60
SLC7A11	expressed_in	gene	0.60
hippocampus	expressed_in	brain_region	0.60
GPX4	inhibits	gene	0.60
SLC7A11	inhibits	gene	0.60
TFR1	activates	gene	0.60
ferroptosis	participates_in	pathway	0.60
ROS	expressed_in	gene	0.60
WDR45	interacts_with	gene	0.60
neurodegeneration	interacts_with	disease	0.60
Autophagy	associated_with	pathway	0.60
GPX4	activates	gene	0.60
SLC7A11	activates	gene	0.60
PANK2	interacts_with	gene	0.60
PLA2G6	interacts_with	gene	0.60
Mitophagy	associated_with	pathway	0.60
OXIDATIVE STRESS	inhibits	gene	0.60
Lipid Metabolism	associated_with	pathway	0.60
Oxidative Stress	treats	pathway	0.60

Incoming (47)

Source	Relation	Type	Str
ALZHEIMER'S DISEASE	treats	gene	0.60
FERROPTOSIS	inhibits	gene	0.60
DJ-1	expressed_in	gene	0.60
OXIDATIVE STRESS	inhibits	gene	0.60
ALZHEIMER	inhibits	gene	0.60
ACSL4	expressed_in	gene	0.60
TFR1	expressed_in	gene	0.60
APP	inhibits	gene	0.60
LGALS3	associated_with	gene	0.60
PI3K	associated_with	gene	0.60
FGF19	associated_with	gene	0.60
PLAU	associated_with	gene	0.60
AKT	associated_with	gene	0.60
TNF	associated_with	gene	0.60
NME1	associated_with	gene	0.60
HSP90AA1	associated_with	gene	0.60
SPP1	associated_with	gene	0.60
APP	treats	gene	0.60
ACSL4	inhibits	gene	0.60
FTH1	inhibits	gene	0.60
FERROPTOSIS	treats	gene	0.60
DEPRESSION	inhibits	gene	0.60
APP/PS1	treats	gene	0.60
OXIDATIVE STRESS	treats	gene	0.60
ALZHEIMER	treats	gene	0.60
FPN1	expressed_in	gene	0.60
FPN1	inhibits	gene	0.60
ACSL4	activates	gene	0.60
GSH	inhibits	gene	0.60
APP/PS1	inhibits	gene	0.60
ALZHEIMER'S DISEASE	inhibits	gene	0.60
GPX4	expressed_in	gene	0.60
SLC7A11	expressed_in	gene	0.60
NRF2	expressed_in	gene	0.60
FTH1	expressed_in	gene	0.60
ATP13A2	interacts_with	gene	0.60
CP	interacts_with	gene	0.60
DCAF17	interacts_with	gene	0.60
FA2H	interacts_with	gene	0.60
DMT1	expressed_in	gene	0.60
DMT1	activates	gene	0.60
FTH1	activates	gene	0.60
ERK	associated_with	gene	0.60
JAK	associated_with	gene	0.60
APOPTOSIS	associated_with	gene	0.60
ACSL4	co_expressed_with	gene	0.50
FTH1	co_expressed_with	protein	0.50

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Labile iron pool expansion amplifies genotype-specific ALS f	0.664	neurodegeneration	Ferroptosis in ALS motor neuron vulnerab
Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 thro	0.595	neurodegeneration	What mechanisms drive TDP-43 pathology s

Mentioning Analyses (2)

Scientific analyses that reference this entity

What molecular mechanisms enable functional recovery and muscle re-innervation a

neurodegeneration | 2026-04-14 | 2 hypotheses Top: 0.683

What mechanisms drive TDP-43 pathology specifically in Alzheimer's disease versu

neurodegeneration | 2026-04-07 | 3 hypotheses Top: 0.595

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

TDP-43 inclusions occur in AD, ALS, and FTLD but the pathogenic mechanisms leadi

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

The study shows dramatic functional recovery and muscle re-innervation after cyt

closed · Rounds: 4 · Score: 0.85 · 2026-04-15

Related Research

Hypotheses and analyses mentioning FTL in their description or question text

No additional research found

FTL

Understanding Entity Pages

Summary

Wiki Pages (12)

FTL Gene

FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation

FTLD-TDP Subtypes and Mechanisms

Ferritin Light Chain (FTL)

Biomarkers to Distinguish FTLD-tau from FTLD-TDP

FTLD-tau Subtypes and Mechanisms

FTLD-ALS: Frontotemporal Lobar Degeneration with Motor Neuron Disease

PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD